Description
Chemical Identity
GLP-1 Analog (31-aa) is a synthetic 31-amino acid peptide with the molecular formula C187H291N45O59 and a molecular weight of 4113.58 Da (CAS number 910463-68-2). The compound features an Aib (alpha-aminoisobutyric acid) substitution at position 8 for DPP-IV resistance and a C18 fatty diacid moiety attached at Lys26 that enables non-covalent albumin binding, extending the pharmacokinetic half-life to approximately 7 days. This GLP-1 analog is also known as semaglutide in the research literature and has been investigated as a glucagon-like peptide-1 receptor agonist.
GLP-1 Analog (31-aa) represents an advanced incretin mimetic designed for once-weekly administration, with both subcutaneous and oral formulations having been developed and studied in clinical trials.
| Property | Value |
|---|---|
| Molecular Formula | C187H291N45O59 |
| Molecular Weight | 4113.58 Da |
| CAS Number | 910463-68-2 |
| Key Modifications | Aib8 substitution; C18 fatty diacid at Lys26 |
| Research Status | FDA-approved (multiple indications) |
Research Overview
GLP-1 Analog (31-aa) has been extensively investigated across clinical development programs for type 2 diabetes, obesity, and cardiovascular disease. The primary mechanism involves potent agonism of the GLP-1 receptor (GLP-1R), a class B GPCR expressed in pancreatic beta cells, the central nervous system, the gastrointestinal tract, and the cardiovascular system. GLP-1R activation stimulates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and activates hypothalamic satiety centers to reduce appetite and food intake.
The fatty acid-mediated albumin binding provides the extended pharmacokinetic profile that enables once-weekly dosing, while the Aib8 substitution prevents inactivation by DPP-IV, the enzyme that rapidly degrades native GLP-1.
Key areas of published research include:
- Weight Management: Clinical trials have demonstrated substantial body weight reduction in obese participants, with Phase 3 studies reporting mean weight loss of approximately 15-17% from baseline at 68 weeks, establishing GLP-1 Analog (31-aa) as one of the most effective pharmacological interventions for obesity.
- Type 2 Diabetes: Extensive clinical programs have demonstrated significant HbA1c reductions with a favorable safety profile, leading to regulatory approvals for glycemic control in type 2 diabetes.
- Cardiovascular Outcomes: The SELECT trial demonstrated significant reduction in major adverse cardiovascular events in overweight/obese adults, expanding the compound’s clinical utility beyond metabolic disease into cardiovascular risk reduction.
GLP-1 Analog (31-aa) has received regulatory approvals for type 2 diabetes and obesity management. Research-grade material is available for preclinical studies.
Specifications
All GLP-1 Analog (31-aa) supplied by Prescott Bio Canada is manufactured to research-grade standards.
| Specification | Detail |
|---|---|
| Purity | >98% (HPLC) |
| Form | Lyophilized powder |
| Appearance | White to off-white powder |
| Storage (lyophilized) | -20°C, protected from light |
| Storage (reconstituted) | 2-8°C, use within 30 days |
| Solubility | Soluble in sterile water or appropriate buffer |
Each vial is accompanied by a Certificate of Analysis (COA) documenting purity, identity, and endotoxin testing.
Research Applications
GLP-1 Analog (31-aa) is supplied exclusively for in vitro and in vivo laboratory research. Published experimental applications include:
- GLP-1 receptor signaling and incretin pathway research
- Metabolic disease and obesity mechanism studies
- Pancreatic beta cell function and insulin secretion research
- Central appetite regulation and hypothalamic signaling studies
- Cardiovascular outcome and cardioprotection research
- Comparative studies with other incretin mimetics and dual/triple agonists
Researchers should consult the primary literature and institutional review protocols before designing experiments with GLP-1 Analog (31-aa).
Storage and Handling
Lyophilized powder: Store at -20°C in the original sealed vial, protected from light and moisture. Under these conditions, GLP-1 Analog (31-aa) maintains stability for up to 24 months.
Reconstituted solution: Reconstitute with sterile water or appropriate buffer. Store reconstituted GLP-1 Analog (31-aa) at 2-8°C and use within 30 days. Avoid repeated freeze-thaw cycles.
Handling precautions: This product is intended for research use only (RUO). Not for human or veterinary diagnostic or therapeutic use. Handle using standard laboratory safety practices including appropriate PPE.